Monoclonal Antibodies in Chronic Lymphocytic Leukemia

Abstract

For decades, alkylating agents have been the mainstay of treatment of chronic lymphocytic leukemia CLL), achieving a modest response. Recently, fludarabine has been shown to induce higher and long‐lasting responses, and has, in many institutions, replaced the alkylating agents as the first‐line agent in the treatment of CLL. However, the goal of achieving higher complete responses that might translate into an improved overall survival in CLL still remains elusive. Antibody‐mediated therapy has emerged as an effective modality in the treatment of low‐grade B‐cell malignancies. Monoclonal antibodies McAb) against specific lymphocyte markers, including CD52 Campath‐1H) and CD20 rituximab), are currently being actively studied in the treatment of CLL. Initial results with Campath‐1H and rituximab in previously treated and untreated patients with CLL have been promising. We present a review of the current status of McAb and their potential role in the future for the treatment of CLL.